Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
SK Telecom Co. has released a mobile app-based DNA testing service dubbed care8 DNA in partnership with its joint venture Invites Healthcare Co. and bio firm Macrogen Inc.
The subscription-based setting allows users to sign up for 29 types of genetic testing, such as for nicotine reliance and hair loss.
Users will receive DNA test kits at home, which they would send back to SK Telecom with their saliva for analysis.
Test results will be available on the care8 DNA app after two weeks.
According to SK Telecom, their DNA service, which costs 99,000 won for a one-year subscription, is more affordable than local direct-to-consumer (DTC) genetic tests.
The app also provides other services, such as personalized health coaching. More genetic tests would also be introduced.
SK Telecom, South Korea's largest mobile carrier, increased its investment in Israel-based startup Nano-X Imaging Ltd in June to boost its presence in the digital health care sector.
The global DTC genetic testing market is expected to increase to $6.4 billion in 2028 from $824 million in 2018.
